SLP Stock Analysis
SL
Neutral
Based on Eyestock quantitative analysis, SLP`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly undervalued
Market cap $B
0.627
Dividend yield
0.60 %
Shares outstanding
20.329 B
Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The company is headquartered in Lancaster, California and currently employs 157 full-time employees. The firm provides prediction of properties of molecules utilizing both artificial intelligence (AI) and machine-based technology. The company also provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. The company offers approximately 13 software products for pharmaceutical research and development, such as GastroPlus, DDDPlus, MembranePlus, ADMET Predictor, MedChem Designer, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite and PKPlus. Its software and consulting services are provided to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and academic and regulatory agencies worldwide for use in the conduct of industry-based research. Its subsidiaries include Cognigen Corporation, DILIsym Services, Inc. and Lixoft.